

NO. 99-06508-M

THURMAN HARMON, et al.	§	IN THE DISTRICT COURT OF
	§	
Plaintiffs,	§	
	§	
V.	§	DALLAS COUNTY, TEXAS
	§	
OWENS CORNING (a/k/a OWENS	§	
CORNING CORPORATION), et al.	§	
	§	
Defendants.	§	298TH JUDICIAL DISTRICT

**DEFENDANT CELANESE LTD.'S DESIGNATION OF
EXPERT WITNESSES**

Defendant Celanese Ltd. ("Defendant") serves the following designation of expert witnesses pursuant to the Texas Rules of Civil Procedure and as a supplement to Defendant's Response to Plaintiff's Request for Rule 194 Disclosures, subpart (f).

1. J. LeRoy Balzer, Ph.D., 408 Horse Trail Court, Alamo, California 94507; (925) 274-0826.

Dr. Balzer has a Bachelor of Science degree in Public Health Microbiology and a Master of Science degree in Preventive Medicine/Public Health, which were awarded by the University of California at Los Angeles in 1962 and 1963, respectively. He earned a Doctor of Philosophy degree in Environmental Health Science/Industrial Hygiene from the University of California at Berkeley in 1971. From 1966 to 1971, he was employed by the University of California School of Public Health as a research associate and research fellow. In 1966, he became involved in a coordinated research program of occupational medicine, industrial hygiene and education of insulation contractors. This intense study of the construction industry was sponsored through grants from the United States Public Health Service and involved observing the work environment of individuals working with asbestos-containing insulation and related products.

Dr. Balzer worked as a certified industrial hygienist from 1973 until 1987 when he became an Assistant Vice Chancellor at the University of California at San Francisco. He retired in 1994 and became a full-time consulting industrial hygienist and was appointed an Assistant Clinical Professor, School of Medicine, University of California Health Sciences. He is a member of the ACGIH (affiliate), AIHA and other professional organizations reflected on Dr. Balzer's curriculum vitae, which

has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases. Dr. Balzer may testify at trial of this case live or by deposition.

Dr. Balzer has other personal knowledge of relevant facts based on his field work involving the use of asbestos-containing products and the surrounding occupational environment, but he also possesses general expertise in his field based upon specialized knowledge, skills and training. Dr. Balzer may offer opinions in this case about the general nature of the working environment in industrial locations such as where plaintiff worked, to include testimony regarding the composition and asbestos content, if any, of products used in such environments and the ability of such products to release asbestos fiber under certain conditions. Dr. Balzer may provide testimony on the availability of materials as substitutes for asbestos-containing products. Dr. Balzer will testify regarding an individual's exposure to asbestos from different media, to include circumstances and occupational settings that may result in direct exposure from persons having contact with asbestos-containing products or equipment, circumstances that may result in lower indirect or bystander exposures for others in the working environment. His testimony will be based, in part, on the results of testing which he has performed or reviewed for products which are the same or substantially similar to those which are anticipated to be discussed in this case. Dr. Balzer will also testify about industrial hygiene principles and methodologies used to determine potential hazards related to asbestos exposure, and how those principles and methodologies have changed over time.

Additionally, Dr. Balzer, based on personal knowledge and a review of medical, scientific and/or technical literature, will provide historical state-of-the-art testimony on the gradual development of knowledge within industry and within the field of industrial hygiene about asbestos exposure levels and suitable control measures. Dr. Balzer will address the evolution of workplace practices available to control exposures to include historical development of the use of respiratory protection in association with the handling of asbestos-containing products. Finally, Dr. Balzer will testify regarding the development over time of governmental standards and regulations pertaining to asbestos, to include the historical evolution of threshold limit values and permissible exposure levels to asbestos developed by professional organizations and government agencies.

2. Lawrence R. Birkner, CIH, CSP, McIntyre, Birkner & Associates, Inc., 2026 El Monte Drive, Thousand Oaks, California 91362-1822; (805) 494-8173.

Mr. Birkner is a certified industrial hygienist and certified safety professional. He received a Bachelor of Science degree from Portland State University in 1973 and a Masters Degree in Occupational Safety and Health at New York University in 1975. Between 1974 - 1976, Mr. Birkner worked closely with Dr. Irvin Selikoff and others at Mount Sinai while employed as a safety and health research specialist at Environmental Sciences Laboratory in New York. From 1976 through 1996, Mr. Birkner worked extensively as a practicing industrial hygienist in American industry;

in the course of that employment, Mr. Birkner worked as a corporate industrial hygienist for Celanese Corporation between 1977 - 1981. Mr. Birkner is a fellow of the AIHA and a member of the other professional industrial hygiene organizations reflected on Mr. Birkner's curriculum vitae, which has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases.

Mr. Birkner will provide testimony regarding the history of industrial hygiene, industrial hygiene methods, exposure levels which trigger diseases associated with dust exposure, good housekeeping measures, and other related matters. He is prepared to testify about respirator history, what constitutes good hygiene practice, and the periods of time from an industrial hygiene standpoint when people and companies became aware of associated health risks. Mr. Birkner may give testimony regarding the level of fiber release, if any, from asbestos-containing products in the occupational setting and may testify regarding the availability of materials as substitutes for asbestos-containing products. He may testify as to issues involving re-entrainment and fiber drift. Mr. Birkner may also testify regarding work practices applicable to various types of occupations using products that contain asbestos, and he will provide a retrospective assessment or estimate of plaintiff's likely exposure to asbestos in a Celanese work environment based on historical literature and the facts available in this case.

Mr. Birkner has personal knowledge of relevant facts, but he also possesses generalized expertise in his field based on his specialized knowledge, skills and training. He may provide testimony regarding the applicability of the ACGIH, OSHA and EPA guidelines as they relate to occupational exposures to various types of asbestos-containing products. Mr. Birkner may testify regarding the size, construction, layout and working environment of facilities such as where plaintiff worked. He may testify about the nature of the working environment in such locations. He may testify about his knowledge of the composition and asbestos content, if any, of products present in the plaintiff's workplace and may testify concerning the ability of such products to emit asbestos fibers under certain conditions. Mr. Birkner may testify to the dust levels produced by particular occupational operations and products, to include those associated with the use of pipe and block insulation.

Mr. Birkner may testify about the development of literature and information about asbestos-related diseases as they relate to the gradual development of knowledge within industry and within the field of industrial hygiene about asbestos exposure and appropriate control measures. He will address the evolution of workplace practices available to control exposures, to include the historical development of the use of respiratory protection in association with the handling of asbestos-containing products. Mr. Birkner will testify regarding the development over time of governmental standards and regulations pertaining to asbestos, to include the historical evolution of permissible exposure levels to asbestos developed by professional organizations and government agencies. He will discuss his own research into asbestos-related diseases as they relate to industrial hygiene, the

carcinogenicity of various fiber types as they relate to industrial hygiene, and the relationship, if any, between asbestos and various diseases. Mr. Birkner will provide testimony regarding the epidemiology of asbestos-related diseases, latency, state-of-the-art, and other related matters as they impact industrial hygiene. Based on the above evidence developed in this case, Mr. Birkner will testify that the plaintiff at issue had little or no opportunity for any harmful exposure to asbestos while working at a Celanese facility because of the nature of plaintiff's occupation and particular working environment, and he will also testify that Celanese's approach to the handling and control of any asbestos-containing materials on its premises were reasonable in light of available information and industrial hygiene practices at different points of time. He may also testify as to any matter raised by experts called by plaintiff or any co-defendants in this action.

3. James D. Crapo, M.D., National Jewish Medical and Research Center, 1400 Jackson Street, Denver, Colorado 80206; (303) 398-1436.

Dr. Crapo received a Bachelor of Science degree from Brigham Young University in 1967 and his medical degree from the University of Rochester New York in 1971. He taught medicine for many years at Duke University in Durham, North Carolina. Dr. Crapo is board certified in internal medicine with a subspecialty certification in pulmonary disease. He presently practices medicine at the National Jewish Medical Center in Denver, Colorado and teaches today at the University of Colorado Health Science Center. Dr. Crapo is a fellow of the American Thoracic Society, the American College of Chest Physicians and other professional organizations reflected on Dr. Crapo's curriculum vitae, which has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases. Dr. Crapo may testify live or by deposition at trial in this matter.

Dr. Crapo is expected to testify about the pulmonary aspects of asbestos exposure, including matters such as dose response, pathogenicity, carcinogenicity and the potential for asbestos-related disease as a result of exposure to the different types of fiber. Dr. Crapo is also expected to testify as to general medical issues and physiology.

Dr. Crapo's testimony is based in part on the personal knowledge of relevant facts, but he also possesses general expertise in his field based upon specialized knowledge, skills and training. Dr. Crapo is expected to testify about alleged occupational exposure – as described by plaintiff and plaintiff's witnesses – and whether such exposure occurred for a sufficient period of time and in a sufficient dose to be of medical consequence, and whether such exposure could be considered a substantial contributing factor to plaintiff's alleged disease. In connection with this, based on his own experience and a review of the medical, scientific and/or technical literature and the opinions and conclusions contained in that literature, Dr. Crapo will provide historical state-of-the-art testimony on the gradual development of knowledge within the medical profession of the asbestos-related illnesses. Dr. Crapo may provide testimony regarding the reasonableness

of Celanese's usage and control of asbestos at its premises from a medical standpoint based on the developing state of medical knowledge concerning asbestos over time.

Dr. Crapo is expected to testify about the principles of epidemiology and what is involved in an epidemiologic study. He is expected to testify that studies of particular groups or occupations of people are not necessarily applicable to other groups or occupations. Dr. Crapo is expected to testify as to the information necessary to determine whether a group of people or persons are at risk for contracting an asbestos-related disease and if it is scientifically possible to attribute a disease to a particular exposure. Dr. Crapo is expected to discuss epidemiological analysis of asbestos-related disease in the context of given levels of exposure, and to discuss how such analysis may be applied to the evidence regarding the plaintiff in this case.

Finally, Dr. Crapo may testify regarding plaintiff's medical condition, cigarette smoking and lung disease, and generally about the pulmonary system and its functions as well as conditions and diseases of the pulmonary system. Dr. Crapo may also testify regarding the diagnosis and prognosis of asbestos-related markers and diseases, and the risks associated with developing cancers. Dr. Crapo may also testify about any matter raised by experts called by plaintiff or any co-defendant, to include but not limited to plaintiff's medical condition, the state of medical knowledge concerning asbestos, asbestos-related disease and other occupational diseases.

4. Dorsett D. Smith, M.D., 4310 Colby Avenue, Suite 201, Everett, Washington 98203; (425) 259-5171.

Dr. Smith received his Bachelor of Arts degree from Colgate University in 1959 and his medical degree from the University of Pennsylvania Medical School in 1963. Dr. Smith is board certified in internal medicine with a subspecialty certification in pulmonary disease. Dr. Smith has taught medicine at Johns Hopkins Hospital and the University of Washington Hospital for many years through the present. Dr. Smith is a NIOSH certified "B" reader and is fellow of the American Thoracic Society, the American College of Chest Physicians, the American College of Occupational and Environmental Medicine and other professional organizations reflected on Dr. Smith's curriculum vitae, which has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases.

Dr. Smith will testify about the pathology of asbestos-related diseases, his research into asbestos-related diseases, the carcinogenicity of various asbestos fiber types, the potential for asbestos-related disease as a result of exposures to the different types of fibers and the relationship, if any, between asbestos and various illnesses. Dr. Smith will also testify regarding the general pulmonary aspects of asbestos exposure, including matters such as dose response, latency and the required fiber burden associated with asbestos-related illnesses. Dr. Smith is expected to testify

about alleged occupational exposure – as described by plaintiff and plaintiff's witnesses – and whether, based on his own experience and his review of the medical, scientific and/or technical literature and the opinions and conclusions contained in that literature, whether any exposure at a facility owned or operated by Celanese could be considered a substantial contributing factor to plaintiff's alleged disease.

Dr. Smith has personal knowledge of certain relevant facts but also possesses general expertise in his field based upon specialized knowledge, skills and training. Based upon his own experience and his review of the medical, scientific and/or technical literature and the opinions and conclusions contained in that literature, Dr. Smith will provide historical state-of-the-art testimony on the gradual development of knowledge within the medical profession about the various diseases associated with asbestos and about the asbestos exposure levels thought to be associated with each disease. Dr. Smith will testify regarding the reasonableness of Celanese's historical usage and control of asbestos in its workplace from a medical standpoint based on the information available in the general medical literature and on the types of preventative measures considered by the general medical community as appropriate in the different decades from 1900 through the present.

Dr. Smith is expected to testify about the principles of epidemiology and what is involved in an epidemiologic study. He is expected to testify that studies of particular groups or occupations of people are not necessarily applicable to other groups or occupations. Dr. Smith is expected to testify as to the information necessary to determine whether a group of people are at risk of contracting a particular asbestos-related disease, and whether it is scientifically possible to attribute a disease to a particular exposure. Dr. Smith is expected to discuss epidemiological analysis of asbestos and how such analysis may be applied to the evidence in this case and to the plaintiff.

Dr. Smith may testify regarding plaintiff's medical condition, cigarette smoking and lung disease, and generally about the pulmonary system and its functions as well as the diagnosis and prognosis of asbestos-related markers and diseases, and the risks associated with developing cancers. Dr. Smith is also expected to testify about any matter raised by experts called by plaintiff or any co-defendant, including but not limited to plaintiff's medical condition, the state of medical knowledge concerning asbestos, asbestos-related disease and other occupational diseases.

5. Mark R. Stenzel, CIH, P.O. Box 850235, Richardson, Texas 75085-0235; (972) 404-3207.

Mr. Stenzel is a practicing certified industrial hygienist. He holds a Bachelor of Science degree in mathematics and chemistry and a Master of Science degree in physical chemistry, which he received from the University of Illinois in 1975. In 1973, Mr. Stenzel was hired by Celanese Chemical Company and worked as a lab chemist/health chemist at its Pampa plant, where he performed industrial hygienist

duties to include air monitoring. He became a certified industrial hygienist for Celanese. In that capacity, he had direct contact with each plant in the company and was the hygiene personnel at the plant, company and corporate levels. In 1983, Mr. Stenzel became Manager of Industrial Hygiene for Celanese and held that position through 1992. Since 1992, he has been otherwise employed in industry as an industrial hygienist. Mr. Stenzel is a member of the AIHA, the American Academy of Industrial Hygienists and other professional organizations reflected on Mr. Stenzel's curriculum vitae, which has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases. Mr. Stenzel may testify at trial live or by deposition.

Most of Mr. Stenzel's testimony will be factual in nature and will address the development of Celanese's industrial hygiene and environmental, safety and health programs from their inception through the 1980s. However, this disclosure is made in an abundance of caution because Mr. Stenzel also possesses general expertise in his field based upon specialized knowledge, skills and training, and some areas of his testimony may be informed by professional judgment and opinion. Mr. Stenzel will address the nature and structure of Celanese's industrial hygiene programs and the industrial hygiene and occupational safety practices adopted at Celanese facilities over time. From a review of company documents and other materials, Mr. Stenzel will testify about air monitoring for asbestos exposure and other workplace substances conducted at Celanese plants and the low exposures/low risk levels indicated by the available monitoring data.

From 1977 forward, Mr. Stenzel was intimately involved in the creation and design of Celanese's Health Monitoring System, to include its worker tracking module, health monitoring module and retrospective exposure assessment module. Mr. Stenzel piloted the worker tracking module, health monitoring module and retrospective exposure assessment module. Mr. Stenzel piloted the worker tracking module at the Pampa plant and helped implement all modules at other Celanese facilities between 1978 – 1981. Mr. Stenzel will testify that the system was state-of-the-art at the time and would be considered state-of-the-art today.

Based on a review of plant and company documents, Mr. Stenzel will testify about how each module system was implemented throughout the company and at each company plant. Mr. Stenzel will provide testimony regarding the correlation of worker tracking exposure data and retrospective exposure data with the alleged exposure claimed by plaintiff. Based on his assessment of these materials, Mr. Stenzel is expected to testify about alleged occupational exposure – as described by plaintiff and plaintiff's witnesses – and the potential risk for developing an occupational disease associated with that exposure. Finally, Mr. Stenzel may provide testimony regarding mortality studies and similar disease assessments which involved the workforce employed at Celanese's plants. The nature of those studies are referenced in the attached curriculum vitae.

6. Ernest M. Dixon, M.D., Sc.D., 6305 Evermay Drive, McLean, Virginia 22101.

Dr. Dixon received his medical degree from the University of Virginia in 1948 and a doctorate in occupational health from the University of Cincinnati in 1957. Dr. Dixon has held various occupational health positions in industry and served as Celanese's corporate medical director from 1966 - 1981. A curriculum vitae is available upon request. Dr. Dixon may testify at trial in this case live or by deposition.

Dr. Dixon's anticipated testimony in this matter is expected to be factual in nature and will address the development of Celanese's occupational health, industrial hygiene and environmental program from their inception through the 1980s. Dr. Dixon will provide testimony regarding the nature and structure of those programs and, from his own experience and observations, the occupational health and safety practices adopted at Celanese's facilities over time. Dr. Dixon will testify that Celanese's plants over time were extremely clean, well maintained and safe premises; that Celanese's occupational health and safety programs were well developed and advanced for their time; that the potential for asbestos exposure at each plant over time was extremely low; and that no worker present at any Celanese plant was considered to be at risk of incurring any asbestos-related illness based on the information reasonably available to the occupational health community during his period of responsibility.

Dr. Dixon's testimony will be factual in nature based on personal knowledge in relevant areas. However, Dr. Dixon also possesses general expertise in the fields of medicine and occupational health based on specialized knowledge, skills and training. This disclosure is made in an abundance of caution because certain aspects of Dr. Dixon's anticipated testimony may be said to involve the exercise of professional judgment and/or the expression of professional opinion.

7. Mr. Charles S. Laubly, 2225 North Tucson Boulevard, Tucson, Arizona 85716.

Mr. Laubly received a Bachelor of Science degree from Georgia Tech in 1949. Mr. Laubly worked as field industrial hygienist thereafter and was employed as a corporate industrial hygienist by Celanese between 1967 - 1979. A curriculum vitae is available upon request. Mr. Laubly may testify at trial in this case live or by deposition.

Mr. Laubly's anticipated testimony in this matter is expected to be factual in nature and will address the development of Celanese's industrial hygiene and environmental programs from their inception through the 1980s. Mr. Laubly will provide testimony regarding the nature and structure of those programs and, from his own experience and observations, the industrial hygiene and safety practices adopted at Celanese's facilities over time. Mr. Laubly will testify that Celanese's plants over time were extremely clean, well maintained and safe premises; that Celanese's industrial hygiene and safety programs were well developed and

advanced for their times; that the usage of asbestos at Celanese's facilities were relatively minor and that the potential for asbestos exposure at each plant over time was extremely low; and that no worker present at any Celanese plant was considered to be at risk of incurring any asbestos-related illness based on the information reasonably available to the occupational health community during his period of responsibility.

Mr. Laubly's testimony will be factual in nature based on personal knowledge in relevant areas. However, Mr. Laubly also possesses general expertise in the field of industrial hygiene based on education, training and experience. This disclosure is made in an abundance of caution because certain aspects of Mr. Laubly's anticipated testimony may be said to involve the exercise of professional judgment and/or the expression of professional opinion.

8. Herbert J. Kolodner, Ph.D., P.E., 777 Pebble Beach Drive, Crescent City, California 95331-3634.

Dr. Kolodner received a Master's degree in safety from the University of Maryland in 1960 and a doctorate in industrial safety from New York University in 1973. Dr. Kolodner has held various safety positions in industry and served as Celanese's corporate safety director from 1970 - 1984. A curriculum vitae is available upon request. Dr. Kolodner may testify at trial in this case live or by deposition.

Dr. Kolodner's anticipated testimony in this matter is expected to be factual in nature and will address the development of Celanese's occupational safety and environmental programs from their inception through the 1980s. Dr. Kolodner will provide testimony regarding the nature and structure of those programs and, from his own experience and observations, the safety practices adopted at Celanese's facilities over time. Dr. Kolodner will testify that Celanese's plants over time were extremely clean, well maintained and safe premises; that Celanese's safety programs were well developed and advanced for their times; that the usage of asbestos at Celanese's facilities were relatively minor and the potential for asbestos exposure at each plant over time was extremely low.

Dr. Kolodner's testimony will be factual in nature based on personal knowledge in relevant areas. However, Dr. Kolodner also possesses general expertise in the field of industrial hygiene based on education, training and experience. This disclosure is made in an abundance of caution because certain aspects of Dr. Kolodner's anticipated testimony may be said to involve the exercise of professional judgment and/or the expression of professional opinion.

9. Carrol W. Whaley, CIH, CSP, 3403 Yerba Buena Road, San Jose, CA 95135.

Mr. Whaley has held various occupational health and industrial hygiene positions in industry and served as Celanese's plant industrial hygienist at the Bay City

facility from 1978 - 1985. A curriculum vitae is available upon request. Mr. Whaley may testify in this case live or by deposition.

Mr. Whaley's anticipated testimony in this matter is expected to be factual in nature and will address the development of Celanese's industrial hygiene and environmental program at the Bay City plant during his employment there. Mr. Whaley will provide testimony regarding the nature and structure of those programs and, from his own experience and observations, the occupational health and safety practices adopted at the facility over time. Mr. Whaley will testify that the Bay City plant over time was an extremely clean, well maintained and safe premises; that Celanese's industrial hygiene and safety programs are well developed and advanced for their time; that the usage of asbestos at Bay City was relatively minor and that the potential for asbestos exposure at each plant over time was extremely low; and that no worker present at any Bay City plant was considered to be at risk of incurring any asbestos-related illness based on the information reasonably available to the occupational health community during his period of responsibility. Mr. Whaley may also provide testimony regarding development and implementation of the health monitoring system at Bay City, to include the retrospective exposure module.

Mr. Whaley's testimony will be factual in nature based on personal knowledge in relevant areas. However, Mr. Whaley also possesses general expertise in the field of industrial hygiene and occupational health based on specialized knowledge, skills and training. This disclosure is made in an abundance of caution because certain aspects of Mr. Whaley's anticipated testimony may be said to involve the exercise of professional judgment and/or the expression of professional opinion.

10. William L. Dyson, PhD., C.I.H., Workplace Hygiene, LLC, 1022 Jefferson Road, Greensboro, North Carolina 27140

Dr. Dyson is a certified industrial hygienist. He received a bachelor of science degree from North Carolina State University in 1973, a master's degree in environmental health engineering from Northwestern University in 1971, and received his doctorate in environmental health engineering from Northwestern University in 1975. From 1967 through 1969, Dr. Dyson worked as a field industrial hygiene engineer for the U.S. Public Health Service providing industrial hygiene services to the public. From 1973 through 1982, Dr. Dyson worked extensively as a practicing industrial hygienist in American industry. Dr. Dyson has worked as a self-employed industrial hygiene consultant from that time through the present. Dr. Dyson is a fellow of the AIHA, a member of the American Academy of Industrial Hygiene, a diplomat of the American Board of Industrial Hygiene, a member of the American Society of Safety Engineers and other professional organizations reflected on the curriculum vitae of Dr. Dyson, which was produced to Baron & Budd in the *Vicente Rodriguez* case.

Dr. Dyson will provide testimony regarding the history of industrial hygiene, industrial hygiene methods, exposure levels which trigger diseases associated with dust exposure, good housekeeping measures, and other related matters. He is prepared to testify about respirator history, what constitutes good hygiene practice, and the periods of time from an industrial hygiene standpoint when people and companies became aware of associated health risks. Dr. Dyson may give testimony regarding the level of fiber release, if any, from asbestos-containing products in the occupational setting and may testify regarding the availability of materials as substitutes for asbestos-containing products. He may testify as to issues involving re-entrainment and fiber drift. Dr. Dyson may also testify regarding work practices applicable to various types of occupations using products that contain asbestos, and he will provide a retrospective assessment or estimate of plaintiff's likely exposure to asbestos in a Celanese work environment based on historical literature and the facts available in this case.

Dr. Dyson has personal knowledge of relevant facts, but he also possesses generalized expertise in his field based on his specialized knowledge, skills and training. He may provide testimony regarding the applicability of the ACGIH, OSHA and EPA guidelines as they relate to occupational exposures to various types of asbestos-containing products. Dr. Dyson may testify regarding the size, construction, layout and working environment of facilities such as where plaintiff worked. He may testify about the nature of the working environment in such locations. He may testify about his knowledge of the composition and asbestos content, if any, of products present in the plaintiff's workplace and may testify concerning the ability of such products to emit asbestos fibers under certain conditions. Dr. Dyson may testify to the dust levels produced by particular occupational operations and products, to include those associated with the use of pipe and block insulation.

Dr. Dyson may testify about the development of literature and information about asbestos-related diseases as they relate to the gradual development of knowledge within industry and within the field of industrial hygiene about asbestos exposure and appropriate control measures. He will address the evolution of workplace practices available to control exposures, to include the historical development of the use of respiratory protection in association with the handling of asbestos-containing products. Dr. Dyson will testify regarding the development over time of governmental standards and regulations pertaining to asbestos, to include the historical evolution of permissible exposure levels to asbestos developed by professional organizations and government agencies. He will discuss his own research into asbestos-related diseases as they relate to industrial hygiene, the carcinogenicity of various fiber types as they relate to industrial hygiene, and the relationship, if any, between asbestos and various diseases. Dr. Dyson will provide testimony regarding the epidemiology of asbestos-related diseases, latency, state-of-the-art, and other related matters as they impact industrial hygiene. Based on the above evidence developed in this case, Dr. Dyson will testify that the plaintiff at issue had little or no opportunity for any harmful exposure to asbestos while

working at a Celanese facility because of the nature of plaintiff's occupation and particular working environment, and he will also testify that Celanese's approach to the handling and control of any asbestos-containing materials on its premises were reasonable in light of available information and industrial hygiene practices at different points of time. He may also testify as to any matter raised by experts called by plaintiff or any co-defendants in this action.

11. William G. Hughson, M.D., PhD., Center for Occupational and Environmental Medicine, UCSD Medical Center, 200 West Arbor Drive, San Diego, California 92103-8800

Dr. Hughson received his bachelor of science degree from the University of Calgary in 1970 and his medical degree from that same institution in 1973. He received his doctorate in epidemiology from Oxford University in 1977. Dr. Hughson is board certified in internal medicine with subspecialty certifications in pulmonary medicine and occupational medicine. Dr. Hughson has taught medicine at the University of California, San Diego for many years through the present. Dr. Hughson is a fellow of the American Thoracic Society, The American College of Chest Physicians, The American College of Occupational and Environmental Medicine and other professional organizations reflected on Dr. Hughson's curriculum vitae, which was produced to Baron & Budd in the *Vicente Rodriguez* case.

Dr. Hughson will testify about the pathology of asbestos-related diseases, his research into asbestos-related diseases, the carcinogenicity of various asbestos fiber types, the potential for asbestos-related disease as a result of exposures to the different types of fibers and the relationship, if any, between asbestos and various illnesses. Dr. Hughson will also testify regarding the general pulmonary aspects of asbestos exposure, including matters such as dose response, latency and the required fiber burden associated with asbestos-related illnesses. Dr. Hughson is expected to testify about alleged occupational exposure – as described by plaintiff and plaintiff's witnesses – and whether, based on his own experience and his review of the medical, scientific and/or technical literature and the opinions and conclusions contained in that literature, whether any exposure at a facility owned or operated by Celanese could be considered a substantial contributing factor to plaintiff's alleged disease.

Dr. Hughson has personal knowledge of certain relevant facts but also possesses general expertise in his field based upon specialized knowledge, skills and training. Based upon his own experience and his review of the medical, scientific and/or technical literature and the opinions and conclusions contained in that literature, Dr. Hughson will provide historical state-of-the-art testimony on the gradual development of knowledge within the medical profession about the various diseases associated with asbestos and about the asbestos exposure levels thought to be associated with each disease. Dr. Hughson will testify regarding the reasonableness of Celanese's historical usage and control of asbestos in its workplace from a medical standpoint based on the information available in the

general medical literature and on the types of preventative measures considered by the general medical community as appropriate in the different decades from 1900 through the present.

Dr. Hughson is expected to testify about the principles of epidemiology and what is involved in an epidemiologic study. He is expected to testify that studies of particular groups or occupations of people are not necessarily applicable to other groups or occupations. Dr. Hughson is expected to testify as to the information necessary to determine whether a group of people are at risk of contracting a particular asbestos-related disease, and whether it is scientifically possible to attribute a disease to a particular exposure. Dr. Hughson is expected to discuss epidemiological analysis of asbestos and how such analysis may be applied to the evidence in this case and to the plaintiff.

Dr. Hughson may testify regarding plaintiff's medical condition, cigarette smoking and lung disease, and generally about the pulmonary system and its functions as well as the diagnosis and prognosis of asbestos-related markers and diseases, and the risks associated with developing cancers. Dr. Hughson is also expected to testify about any matter raised by experts called by plaintiff or any co-defendant, including but not limited to plaintiff's medical condition, the state of medical knowledge concerning asbestos, asbestos-related disease and other occupational diseases.

12. Peter J. Barrett, M.D., 300 Boylston Street, Suite 714, Boston, Massachusetts 02116-3923

Dr. Barrett received his bachelor of arts degree from the College of The Holy Cross in 1964 and his medical degree from Tufts University School of Medicine in 1968. Dr. Barrett is board certified in diagnostic radiology and nuclear medicine. Dr. Barrett has taught radiology at Harvard University and at other institutions over the years. He is a NIOSH certified "B" reader and is a fellow of the American Thoracic Society, the American College of Chest Physicians, the American College of Radiology and other professional organizations reflected on Dr. Barrett's curriculum vitae, which was produced to Baron & Budd in the *Vicente Rodriguez* case.

Dr. Barrett is expected to testify generally about radiologic concepts and evaluation and their relation to the diagnosis of pulmonary diseases. He will testify specifically regarding his evaluation of x-rays and CT scans in the diagnosis of occupational pneumoconiosis. It is anticipated that Dr. Barrett will testify generally as to his interpretation of the plaintiff's chest images, the presence or absence of any asbestos-related condition as evidenced by those films, and the presence of other abnormalities or conditions unrelated to any exposure to asbestos. In addition, Dr. Barrett is expected to testify generally about the pulmonary affects of asbestos exposure including matters such as dose response, pathogenicity, carcinogenicity and the potential for asbestos-related disease as a result of exposure to the different types of fibers. Dr. Barrett may testify regarding plaintiff's general medical

condition, cigarette smoking history and lung disease, and generally about the pulmonary system and its functions as well as the diagnosis and prognosis of asbestos-related markers and diseases, and the risks associated with developing cancers. Dr. Barrett is also expected to testify about any matter raised by experts called by plaintiff or any co-defendant, including but not limited to plaintiff's medical condition, the state of medical knowledge concerning asbestos, asbestos-related disease and other occupational diseases. In that sense, his testimony may be dependent upon the prior testimony of other experts and cannot be specifically predicted. Dr. Barrett may testify live at trial or by deposition transcript.

13. John R. Holcomb, M.D. 4410 Medical Drive, San Antonio, Texas 78229-0373; 210-692-9400

Dr. Holcomb will testify concerning examination and diagnosis of the physical condition of the plaintiff and/or his medical records. He may testify concerning the overall condition and the relationship of plaintiff's condition, if any, to plaintiff's exposure to asbestos. He may also testify concerning (a) anatomy and function of the respiratory and circulatory systems; (b) nature of asbestos; (c) the symptomatology, disease process and diagnosis of asbestosis and cancer associated with respiratory system, peritoneum, and peritoneal cavity; (d) the nature and extent of medical and scientific knowledge regarding any association of obstructive pulmonary disease with asbestos fiber exposure; (e) the effect of exposure to substances other than asbestos on the development and manifestation of obstructive and restrictive conditions and diseases of the respiratory system; (f) methods of diagnosis of various diseases, particularly the means of establishing the differential diagnosis of alleged asbestos-related diseases with other non-asbestos related diseases; (g) incidence of lung cancer among individuals with asbestosis compared with non-asbestotic asbestos workers and with the general population; (h) cigarette smoking and its effects on the lung; (i) the relationship of cigarette smoking to cancer of the lung and cancers of other sites with reference to epidemiological studies and physiologic effect; (j) difference between impairment and disability; (k) effect of asbestosis on disability and life expectancy; (l) the lack of a relationship between the presence of pleural plaques and a later development of any form of cancer; and (m) historical and/or medical literature. Dr. Holcomb's C.V. has already been provided to Baron & Budd in connection with the *May* and *Dolezal* cases.

See independent medical examination report prepared by Dr. Holcomb attached as Exhibit A.

14. Subject to the right to object to and contest qualifications and admissibility as provided in the Texas Rules of Evidence 702 through 705 and the law of this state, Defendant cross-designates plaintiff's expert witnesses as follows:

- a) All experts identified in Plaintiffs' Disclosures Pursuant to Texas Rule of Civil Procedure 194 filed on or about October 15, 1999;
 - b) Peter A. Petroff, M.D., F.A.C.P., F.C.C.P.
Santa Rosa Northwest Tower II
2833 Babcock Rd., Suite 435
San Antonio, Texas 78229
(210) 614-5855
Plaintiff's treating physician
15. Subject to the right to object to and contest qualifications and admissibility as provided in the Texas Rules of Evidence 702 through 705 and the laws of this state, Defendant designates the following treating physicians of plaintiff:
- a) Dr. Roberto Braglia
714 Booty Street
Corpus Christi, Texas 78404
(361) 888-4441
 - b) Physicians at Christus Spohn Hospital Kleberg
1311 General Cavazos Blvd.
Kingsville, Texas 78363
(361) 595-1661
 - c) Physicians at Christus Spohn Hospital Shoreline/
Spohn Health System
600 Elizabeth Street
Corpus Christi, Texas 78404
(361) 881-3000
 - d) Physicians at Coastal Cardiology Associates
613 Elizabeth, Suite 402
Corpus Christi, Texas 78404-2289
(361) 887-2900
 - e) Dr. Peter Petroff
2833 Babcock Rd., Suite 435
Santa Rosa, S.W. Tower II
San Antonio, Texas 78229
(210) 614-5855

- f) Dr. Arnoldo Villarreal
1521 S. Staples St., Suite 204
Corpus Christi, Texas 78404
(361) 882-4584
or
Kingsville Medical Center
1311 General Cavazos
Kingsville, Texas 78363
- g) Dr. John W. Arringdale
1521 S. Staples, Ste. 604
Corpus Christi, Texas 78404
(512) 887-7474
- h) Dr. Marty Perez
613 Elizabeth, Ste. 804
Spohn Towers
Corpus Christi, Texas 78404
(361) 884-2875
- i) Physicians at Bay Area Surgery
7101 S. Padre Island Dr.
Corpus Christi, Texas 78412
(361) 985-3500
- j) Dr. Julio Vela
4617 Bonner
Corpus Christi, Texas 78411
(361) 853-5033
- k) Dr. O.J. Rodriguez
1021 Senator Carlos Truan Blvd.
Kingsville, Texas 78363
(361) 595-5556
- l) Dr. Roy J. Hotz
1021 Senator Carlos Truan
Kingsville, Texas 78363
Or
2005 C Medical Parkway
San Marcos, Texas 78666
(512) 396-3911

- m) Dr. Joseph Garcia
613 Elizabeth
Corpus Christi, Texas 78404
(361) 887-2900
- n) Dr. Lewis Mandell
1021 Senator Carlos Truan
Kingsville, Texas 78363
Phone number unknown
- o) Dr. Truman Appel
1521 South Staples
Corpus Christi, Texas 78404
Or
1001 Louisiana Ave. #101
Corpus Christi, Texas 78404
(361) 884-4197


The above-listed treating physicians are anticipated to testify regarding plaintiff's medical history, treatment, diagnosis and prognosis based upon their treatment of plaintiff, and they may testify live at trial or by deposition.

16. Defendant further cross-designates any and all experts designated by other defendants in this action.

Defendant reserves the right to amend or supplement this disclosure pursuant to Rule 193.5 of the Texas Rules of Civil Procedure. Defendant further reserves the right to call undesignated expert witnesses in rebuttal, whose identities and testimony cannot reasonably be foreseen until plaintiff's named experts provide written reports in this case and/or have presented testimony and evidence at trial.

Respectfully submitted,

KASOWITZ, BENSON, TORRES
& FRIEDMAN LLP

 By Permission
EMC
Ellen B. Malow
State Bar No. 12888280
Angela R. Hoyt
State Bar No. 00796783
700 Louisiana Street, Suite 2200
Houston, Texas 77002-2730
(713) 220-8800
(713) 222-0843 (Facsimile)

HAWKINS & PARNELL, LLP

Michael E. Hutchins
4000 SunTrust Plaza
303 Peachtree Street, N.E.
Atlanta, Georgia 30308
(404) 614-7400
(404) 614-7500 (Facsimile)

ATTORNEYS FOR DEFENDANT
CELANESE LTD.

OF COUNSEL:

Marc E. Kasowitz
Hector Torres
KASOWITZ, BENSON, TORRES
& FRIEDMAN LLP
1633 Broadway
New York, New York 10019
(212) 506-1700
(212) 506-1800 (Facsimile)

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the foregoing has been served via facsimile, hand delivery and/or by United States mail, postage prepaid, to all counsel of record on this 8th day of November 2000.

Angela R. Hoyt - By Permission
Angela R. Hoyt EMA

JOHN R. HOLCOMB, M.D., P.A.
Pulmonary Diseases
4410 Medical Drive, Suite 440
San Antonio, Texas 78229
(210) 692-9400

October 18, 2000

Angela Hoyt
Kasowitz, Benson, Torres, and Friedman, LLP
700 Louisiana Street, Suite 2200
Houston, Texas 77002

RE: FIDENCIO SANCHEZ


Dear Ms. Hoyt:

Enclosed find a recent evaluation performed for Mr. Fidencio Sanchez in response to an issue of possible asbestos exposure.

Mr. Sanchez has no evidence of asbestos-related lung disease.

Please feel free to call if you have questions or comments.

Sincerely,

A handwritten signature in black ink, appearing to be 'J. Holcomb', written over the printed name.

John R. Holcomb, M.D.

JRH/rh
10/23/00

INITIAL EVALUATION

PATIENT: FIDENCIO SANCHEZ

DATE: 10/18/00

CHIEF COMPLAINT: "Asbestos exposure."

HISTORY OF PRESENT ILLNESS: This 72 year-old, retired laborer left work in 1991, where he was employed by Texas A&I University as a maintenance worker. He had worked there for some 20 years doing minor repair jobs involving plumbing, windows, building and grounds maintenance, door repair, and other non-contracted jobs. He believes he may have had asbestos exposure in previous work for a contractor at the Celanese plant in Bishop, Texas, where he was employed for the nine years previously. During that work, he was a laborer, and fulfilled a variety of requirements, specifically remembering having mixed shovels of material with water to provide covering (presumably insulation) for heat-conducting piping. He reports his work was inside and out, frequently involved with clean-up, and frequently dusty. He is unable to quantify exactly how much of his job was spent doing work which dealt with insulation, and he did not apply insulation himself. He probably worked in the environment where insulators were working, but he cannot really provide those details.

Prior to that time, he was employed by a construction company in similar work, and before that, he was employed in a slaughter house. He did not serve in the military other than the National Guard.

When asked about his current health, he believes it is fairly good, reporting he gets tired easily, but that his only identified medical problem is diabetes mellitus. He has had diabetes for 14-15 years, and he checks his blood sugars at home and generally keeps them between the 120 and 150 range.

In 1997, he was hospitalized in Corpus Christi, Texas, where he underwent four-vessel bypass. It is difficult for me to establish the clinical circumstances that led up to that, and he has done "fine" since, and does not take any cardiac medications. In 1991, he was hospitalized for a procedure that neither he nor his daughter can define. His current medications only include an oral hypoglycemic. He is scheduled for cataract eye surgery in the future.

FAMILY HISTORY: Remarkable for a sister and a mother with diabetes mellitus.

SOCIAL HISTORY: He smoked for 4-5 years when he was young; this apparently was not significant.

REVIEW OF SYSTEMS: Unremarkable. He does describe some ankle swelling involving the left leg only, but that was the site of his saphenous vein harvest for his coronary artery bypass surgery.

PHYSICAL EXAMINATION: Generally, this is a pleasant, elderly man who appears approximately his stated age. Temperature is 96.1; respirations are 20 and unlabored; blood pressure is 138/78; height is 66 inches; and weight is 180 pounds.

FIDENCIO SANCHEZ
Initial Evaluation
Page 2


HEAD, EYES, EARS, NOSE AND THROAT EXAMINATION: normal tympanic membranes and normal fundi bilaterally. The oropharynx is unremarkable. NECK: supple; no carotid bruits are heard; no JVD. CHEST EXAMINATION: clear to auscultation. HEART: regular rhythm; a short systolic ejection murmur is noted along the left sternal border; there is a well-healed median sternotomy wound. ABDOMEN: soft, non-tender, benign. EXTREMITIES: no edema. NEUROLOGIC EXAMINATION: grossly unremarkable.

Chest x-ray today demonstrates normal bony structures and the expected findings of a median sternotomy with evidence of coronary artery bypass via bypass rings. Staples are noted along the left cardiomedial silhouette consistent with left internal mammary artery implant. The parenchyma is unremarkable. The diaphragms are suggestive of hyperexpansion. No pleural abnormalities are noted.

Pulmonary functioning testing is performed; spirometry is normal, although there is a suggested improvement (less than 15%) post-bronchodilator. Total lung capacity and diffusion are also normal.

IMPRESSION: 1. Coronary artery disease; S/P coronary artery bypass grafting, 1997.
2. Diabetes mellitus.

RECOMMENDATIONS: 1. None.



John R. Holcomb, M.D.
JRH/rh
10/23/00

LUNG DIAGNOSTICS OF SAN ANTONIO INC.
PULMONARY FUNCTION LABORATORY

PT: FIDENCIO SANCHEZ
PT#: 455-32-4766
AGE: 72 SEX: M
PHYSICIAN: JRH

TECH: LTR


HT: 66.0 in DATE: 10/18/2000
WT: 180.0 lb TIME: 09:12:46
BP: 741 TEMP: 21.3
PRED-COLLINS2

Spirometry		Pre-Drug*			Post-Drug*		
		Actual	Predicted	%Predicted	Post	%Post	%Change
FVC	(L)	2.97	3.22	92	3.40	105	14
FEV1	(L)	2.32	2.53	92	2.64	104	13
FEV1/FVC	(%)	78	79	99	78	98	0
FEV3	(L)	2.81	3.08	91	3.12	101	11
FEV3/FVC	(%)	94	96	99	92	96	-2
FEF25-75%	(L/S)	2.23	2.58	87	2.48	96	10
FEFmax	(L/S)	3.66	7.25	51	4.72	65	28
FEF25%	(L/S)	3.45	6.61	52	4.18	63	21
FEF50%	(L/S)	2.94	3.29	89	4.18	127	42
FEF75%	(L/S)	0.84	1.06	80	0.76	72	-9
FIF25-75%	(L/S)	2.56			2.65		3
FIF25%	(L/S)	2.37			2.55		7
FIF50%	(L/S)	2.62			2.37		-9
FIF75%	(L/S)	2.07			2.18		5

Lung Volumes		Pre-Drug* Avg		
		Actual	Predicted	%Predicted
TLC	(L)	5.63	5.51	102
FRC	(L)	3.05	3.04	100
RV	(L)	2.62	2.30	114
VC	(L)	3.01	3.22	93
IC	(L)	2.58	2.47	104
ERV	(L)	0.43	0.74	58
RV/TLC	(%)	47	41	112

Diffusion		Pre-Drug* Avg		
		Actual	Predicted	%Predicted
Dsb ml/min/mmHg		20.96	23.68	89
Dsb(adj) ml/min/mmHg		20.96	23.68	89
VA(sb) (L)		4.33	5.51	79
D/VA		4.87	4.30	113
D/VA(adj)		4.87	4.30	113
Hb (gm/100ml)		14.60		

INTERPRETATION: Normal spirometry, static lung volumes, and diffusion.



John R. Holcomb
John R. Holcomb, M.D.

ANDREWS, BELL, MORALES LLC
4410 MEDICAL DRIVE, SUITE 440
SAN ANTONIO, TX 78229
LUNG PATIENT

NEW

18444

Fed. I.D.

Insurance ID

SSN 455-32-4766

Account: 2001366
Insured:

Date: 10/18/00
Primary Insurance Company:

Ime-
8.30

Patient Name
2003435 FIDENCIO SANCHEZ
Birthdate Sex Phone
07/27/20 M 713-222-0843
Relation Employer
SELF

Secondary Insurance

DESCRIPTION	CODE	FEE	DESCRIPTION	CODE	FEE	DESCRIPTION	CODE	FEE
OFFICE VISITS			EKG w/o interp	93005		INJECTIONS		
Office Consultation 1	99241		Venipuncture	36415		Pneumovax	90732	
Office Consultation 2	99242		Hematocrit	85014		Influenza Vaccine	90724	
Office Consultation 3	99243		Potassium	84132		Skin Test, Tuberculosis	86580	
Office Consultation 4	99244		Theophylline Level	80198		Decadron 1cc	J1100	
Office Consultation 5	99245	275	Urinalysis	81000		Decadron 2cc	J1100	
Office Follow-Up 2	99212		CBC w/Differential	85028		Vitamin B12 1cc	J3420	
Office Follow-Up 3	99213		ESR (erythrocyte sedimentatio	85651		Rocaphine 250mg	J0696	
Office Follow-Up 4	99214		Prothrombin Time (PT)	85610		Rocephine 500mg	J0696	
Office Follow-Up 5	99215		Partial Thromboplastin (PTT)	85730		Rocephine 1gm	J0696	
Office New Patient 1	99201		Electrolytes	80004		Terbutaline	J3105	
Office New Patient 2	99202		Glucose	82947		Flu vacc. adm.	G0008	
Office New Patient 3	99203		Multichem	80019		Pneumovax adm.	G0009	
Office New Patient 4	99204		Urine Culture	87086		X-RAYS		
Office New Patient 5	99205		Urine Culture w/Sensitivity	87999		Chest, PA and Lat.	71020	16
LABORATORY			Sputum Culture & Stain	87070		Chest, Single View/100	71010	
Spirometry	94010		Sputum Gram Stain	87205		SLEEP STUDIES		
Bronchospasm Eval.	94060	95	Tubercle Culture	87117		SLST	95810-26	
Oximetry	94760		TB Stain (AFB direct smear)	87206		MSLT	95805-26	
CD Diffusing Capacity	94720	85	Hypothyroid Panel	80091		SLSM	95807-26	
Residual Air (HE Method)	94240	90	Hyperthyroid Panel	80091				
Max. Breathing Capacity	94200		Thoracentesis	32000		TOTAL		585
Flow Volume Loop	94375		Tray, Thoracentesis	A4550		Rec'd Cash		
Nebulization	94664					Rec'd Check		
IPPB Treatment	94650					Rec'd MC/VISA		
ECG w/interp	93000					Credit Adjust		

INSTRUCTIONS:

DIAGNOSIS:

PHYSICIAN'S SIGNATURE

1. Coronary Artery Disease
2. DIABETES MELLITUS
3.
6.

KASOWITZ, BENSON, TORRES & FRIEDMAN LLP

700 LOUISIANA STREET, SUITE 2200

HOUSTON, TEXAS 77002

713-220-8800

FACSIMILE: 713-222-0843

WRITER'S DIRECT DIAL NUMBER

(713) 220-8864

1633 BROADWAY
NEW YORK, NEW YORK 10019
212-506-1700

ONE GATEWAY CENTER
NEWARK, NEW JERSEY 07102
973-645-9462

October 16, 2000

**VIA CERTIFIED MAIL --
RETURN RECEIPT REQUESTED**

Stephanie Finch
BARON & BUDD
A PROFESSIONAL CORPORATION
The Centrum
3102 Oak Lawn Avenue, Suite 1100
Dallas, Texas 75219

Re: *Thurman Harmon, et al. v. Owens Corning (a/k/a Owens Corning Corporation), et al.*, Cause No. 99-06508, in the 298th Judicial District Court, Dallas County, Texas

Dear Ms. Finch:

Enclosed please find the following documents:

- 1) Defendant Celanese Ltd.'s Designation of Expert Witnesses; and
- 3) Defendant Celanese Ltd.'s Certificate of Discovery.

Very truly yours,


Angela R. Hoyt

ARH/ile
Enclosures

KASOWITZ, BENSON, TORRES & FRIEDMAN LLP

700 LOUISIANA STREET, SUITE 2200

HOUSTON, TEXAS 77002

713-220-8800

FACSIMILE: 713-222-0843

WRITER'S DIRECT DIAL NUMBER

(713) 220-8817

1633 BROADWAY
NEW YORK, NEW YORK 10019
212-506-1700

ONE GATEWAY CENTER
NEWARK, NEW JERSEY 07102
973-645-9462

November 8, 2000

**VIA CERTIFIED MAIL –
RETURN RECEIPT REQUESTED**

Mr. Jim Hamlin
Dallas County District Clerk
1st Floor, George L. Allen, Sr. Courts Bldg.
600 Commerce Street
Dallas, Texas 75202-4606

Re: No. 99-06508-M; *Thurman Harmon, et al. v. Owens Corning, et al.*; In
the 298th Judicial District Court of Dallas County, Texas

Dear Mr. Hamlin:

Enclosed for filing in the above-referenced matter is an original and one copy of
Defendant Celanese Ltd.'s Certificate of Discovery pertaining to Celanese Ltd.'s
Designation of Expert Witnesses.

Please acknowledge filing of the above Certificate of Discovery by placing your file
stamp on the copy provided and returning it to me in the enclosed stamped, self-addressed
envelope.

Thank you for your assistance in this matter.

Very truly yours,


Angela R. Hoyt

ARH/llc
Enclosures

cc: Counsel of Record

NO. 99-06508-M

THURMAN HARMON, et al.,

Plaintiffs,

vs.

OWENS CORNING (a/k/a OWENS
CORNING CORPORATION), et al.,

Defendants.

§
§
§
§
§
§
§
§
§

IN THE DISTRICT COURT

DALLAS COUNTY, TEXAS

298TH JUDICIAL DISTRICT

**DEFENDANT CELANESE LTD.'S
CERTIFICATE OF DISCOVERY**

I, Angela R. Hoyt, counsel for Defendant Celanese Ltd., certify that on this the 8th day of November, 2000, I served the following discovery by certified mail, return receipt requested, on the respective attorneys of record for Plaintiffs:

Defendant Celanese Ltd.'s Designation of Expert Witnesses.

Respectfully submitted,

KASOWITZ, BENSON, TORRES
& FRIEDMAN LLP

 By Permission
EMG

Ellen B. Malow

State Bar No. 12888280

Angela R. Hoyt

State Bar No. 00796783

700 Louisiana Street, Suite 2200

Houston, Texas 77002-2730

(713) 220-8800

(713) 222-0843 (Facsimile)

HAWKINS & PARNELL

Albert H. Parnell
State Bar No. 00789876
Michael E. Hutchins
4000 SunTrust Plaza
303 Peachtree Street, N.E.
Atlanta, Georgia 30308
(404) 614-7400
(404) 614-7500 (Facsimile)


ATTORNEYS FOR DEFENDANT
CELANESE LTD.

OF COUNSEL:

Marc E. Kasowitz
Hector Torres
KASOWITZ, BENSON, TORRES
& FRIEDMAN LLP
1633 Broadway
New York, New York 10019
(212) 506-1700
(212) 506-1800 (Facsimile)

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the foregoing has been served via United States certified mail, return receipt requested, on counsel for plaintiffs on this 2nd day of November, 2000.

 By Permission
Angela R. Hoyt ENG